SafeBoosC-IIIv - Does Cerebral Oximetry Monitoring Affect Renal Outcomes
Launched by ST. JOHN'S RESEARCH INSTITUTE · Apr 11, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The SafeBoosC-IIIv clinical trial is studying whether a special monitoring technique called cerebral oximetry can help improve kidney health in newborns who are on a ventilator. This method helps doctors keep the right balance of blood flow and oxygen to the brain, which is important because low blood pressure can increase the risk of kidney injury in these vulnerable babies. By stabilizing blood pressure and oxygen levels, the hope is to reduce the chances of kidney problems.
To be eligible for this trial, newborns need to be over 28 weeks of gestation and require invasive ventilation. Unfortunately, babies with major physical abnormalities cannot participate. If eligible, participants will be closely monitored as doctors implement the SafeBoosC treatment guidelines to see if it positively impacts their kidney health. This trial is currently not recruiting participants, but it aims to provide valuable insights into improving care for newborns with respiratory challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \> 28 weeks of gestation Invasively ventilated
- Exclusion Criteria:
- • major anomalies
About St. John's Research Institute
St. John's Research Institute is a leading clinical research organization dedicated to advancing healthcare through innovative research and development. Affiliated with St. John's Medical College and Hospital in Bangalore, India, the institute focuses on a wide range of biomedical and clinical studies, emphasizing translational research that bridges the gap between laboratory discoveries and patient care. With a commitment to ethical practices and rigorous scientific standards, St. John's Research Institute collaborates with national and international partners to facilitate cutting-edge clinical trials, aiming to develop effective therapeutic solutions and improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bengaluru, Karnataka, India
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported